Suspected Pemphigus Vulgaris
Flaccid blisters/erosions, positive Nikolsky sign, mucosal involvement
All Pathways
DermatologyManagement
Pemphigus Vulgaris Acute Management
Pemphigus Vulgaris Acute Management: Suspected Pemphigus Vulgaris → Confirm Diagnosis → Assess Disease Severity → Mild Disease → Systemic Corticosteroids.
Pathway Overview
13 steps
Algorithm Steps
13 total
01Start 02Action Confirm Diagnosis
Requires histology and immunofluorescence
- Skin biopsy: Intraepidermal acantholysis
- Direct IF: IgG/C3 intercellular (chicken-wire pattern)
- Indirect IF: Serum anti-desmoglein antibodies
- ELISA: Anti-Dsg1 (cutaneous) and Anti-Dsg3 (mucosal)
- Tzanck smear: Acantholytic cells (screening)
03Decision Assess Disease Severity
Based on extent and clinical impact
- Mild: Limited lesions, manageable symptoms
- Moderate: Multiple sites, functional impairment
- Severe: Extensive (>30% BSA), poor nutrition, high anti-Dsg titers
04Action Mild Disease
Limited involvement, localized lesions
- May attempt topical first
- Super-potent topical steroids (clobetasol)
- Oral prednisone 0.5 mg/kg/day if topicals fail
- Close monitoring for progression
05Action Systemic Corticosteroids
Backbone of initial therapy
- Prednisone 0.5-1 mg/kg/day (max ~60-80mg/day)
- Higher doses (1-1.5 mg/kg) for severe disease
- Continue until disease control (no new lesions)
- Then slow taper over 6-12 months
- Pulse IV methylprednisolone for severe: 500-1000mg x3 days
06Action Supportive Care
Essential for all patients
- Wound care: Non-adherent dressings, gentle handling
- Oral care: Soft diet, topical anesthetics, magic mouthwash
- Infection prevention: Culture if suspicious, avoid prophylactic antibiotics
- Nutrition: High protein, supplements if needed
- Pain management
- Steroid side effect prevention: PPI, calcium/vitamin D, bone protection
07Action Treatment Monitoring
Assess response and adjust therapy
- Disease control: No new lesions for 2 weeks, healing of existing
- Consolidation: 80% healed, no new lesions
- Anti-Dsg titers: May correlate with disease activity
- For rituximab: Monitor CD19/CD20 counts
- Taper steroids once consolidated
08Outcome Complete Remission
No lesions on minimal or no therapy
- Complete remission off therapy: Goal
- Complete remission on minimal therapy: Acceptable
- May take 6-24 months to achieve
- Relapse possible - monitor anti-Dsg titers
- Maintenance rituximab may prevent relapse
09Warning Refractory Disease
Failure to respond to standard therapy
- Re-evaluate diagnosis
- Consider: IVIG, plasmapheresis, cyclophosphamide
- Emerging therapies: Bruton tyrosine kinase inhibitors
- Clinical trials may be option
10Action Moderate Disease
Multiple sites, moderate extent
- Systemic therapy required
- Rituximab + prednisone now first-line
- Alternative: Prednisone + azathioprine/MMF
11Action Rituximab (First-Line for Moderate-Severe)
Anti-CD20 monoclonal antibody
- Rheumatoid arthritis protocol: 1000mg IV x2 (Day 0, Day 14)
- OR Lymphoma protocol: 375 mg/m² IV weekly x4
- Pre-medication: Methylprednisolone, acetaminophen, antihistamine
- Combine with prednisone 0.5-1 mg/kg/day
- Complete remission 80-90%
- CONTRAINDICATED in active sepsis/infection
- Path rejoins step 05Shared downstream outcome
12Action Steroid-Sparing Agents
If rituximab unavailable or contraindicated
- Azathioprine: 1-3 mg/kg/day (check TPMT first)
- Mycophenolate mofetil: 2-3 g/day
- Cyclophosphamide: Reserved for refractory cases
- IVIG: 2 g/kg over 2-5 days for rapid control
- Path rejoins step 06Shared downstream outcome
13Warning Severe Disease
Extensive involvement, systemic symptoms
- Often requires hospitalization
- Fluid/electrolyte management
- Nutritional support (dysphagia)
- Infection prevention
- High-dose systemic therapy
- Path rejoins step 11Shared downstream outcome
Guideline Source
EADV S2K Guidelines for Pemphigus Vulgaris and Foliaceus
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Diagnosis requires skin biopsy and immunofluorescence
- Rituximab contraindicated in active infection/sepsis
- Treatment duration individualized based on response
- High-dose steroids carry significant side effect risk
- Specialty management required - not for primary care alone
Applicable Regions
USEU
Version 1Next review: 2027-01-11
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Pemphigus Vulgaris Acute Management?
The Pemphigus Vulgaris Acute Management is a management clinical algorithm for Dermatology. It provides a structured decision tree to guide clinical decision-making, based on EADV S2K Guidelines for Pemphigus Vulgaris and Foliaceus.
What guideline is the Pemphigus Vulgaris Acute Management based on?
This algorithm is based on EADV S2K Guidelines for Pemphigus Vulgaris and Foliaceus (DOI: 10.1111/jdv.16752).
What are the limitations of the Pemphigus Vulgaris Acute Management?
Known limitations include: Diagnosis requires skin biopsy and immunofluorescence; Rituximab contraindicated in active infection/sepsis; Treatment duration individualized based on response; High-dose steroids carry significant side effect risk; Specialty management required - not for primary care alone. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Pemphigus Vulgaris Acute Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free